Sumary of New guideline for juvenile idiopathic arthritis gives emphasis to disease-modifying treatments:
- Reviewed by Emily Henderson, B.Sc.Nov 6 2020 The American College of Rheumatology (ACR) will preview the 2021 Guideline for the Treatment of Juvenile Idiopathic Arthritis at ACR Convergence, the ACR’s annual meeting..
- The new recommendations address pharmacologic and non-pharmacologic treatments and are the culmination of a two-part update of the ACR’s JIA guidelines published in 2011 and 2013..
- It includes treatments for systemic JIA, oligoarthritis, TMJ arthritis, and recommendations for medication monitoring and immunizations..
- We have estimated that half of our patients are cared for by adult rheumatologists, not pediatric rheumatologists, so these recommendations will be helpful for those physicians who may not be as familiar with all the currently available treatments for children with JIA..
- These new approaches are reflected throughout the guideline, which include reduced use of steroids to treat acute inflammation and increased emphasis on biologic drugs now available for JIA that modify disease activity and target the sources of inflammation..
- “Pediatric rheumatologists now more rapidly escalate disease-modifying treatment in JIA patients, and are much less likely to use oral or intravenous steroids..
- Related Stories Another treatment paradigm shift reflected in the new recommendations is how nonsteroidal anti-inflammatory drugs (NSAIDs) should be used to alleviate acute joint pain in JIA patients..
- “In the past, we thought of NSAIDs as a treatment to be used in benign disease, but we have moved away from this approach and now shorten the period of NSAID use based on input from parents and patients..
- “There is a difference between what scientific evidence would support in a treatment recommendation, and how the recommended treatment might affect the quality of life of patients…